Oriol Bestard

Oriol Bestard

Auto-generated profile, based on publicly available information

Oriol Bestard

Kidney Transplant Unit, Nephrology Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2017 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
CLCarmen Lefaucheur
Carmen Lefaucheur
DVDenis Viglietti
Denis Viglietti
LHLuis G. Hidalgo
Luis G. Hidalgo
LRLloyd E. Ratner
Lloyd E. Ratner
SBSerena M. Bagnasco
Serena M. Bagnasco
ALAlexandre Loupy
Alexandre Loupy
Complement-activating anti-HLA donor-specific antibodies (DSAs) are associated with impaired kidney transplant outcome; however, whether these antibodies induce a specific rejection phenotype and influence response to therapy remains undetermined. We prospectively screened 931 kidney recipients for complement-activating DSAs and used histopathology, immunostaining, and allograft gene expression to assess rejection phenotypes. Effector cells were evaluated using in vitro human cell cultures. Additionally, we assessed the effect of complement inhibition on kidney allograft rejection phenotype and the clinical response to complement inhibition in 116 independent kidney recipients with DSAs at transplant receiving rejection prophylaxis with eculizumab or standard of care (plasma exchange and intravenous Ig) at ten international centers. The histomolecular rejection phenotype associated with complement-activating DSA was characterized by complement deposition and accumulation of natural killer cells and monocytes/macrophages in capillaries and increased expression of five biologically relevant genes (CXCL11, CCL4, MS4A7, MS4A6A, and FCGR3A) indicative of endothelial activation, IFNγ response, CD16-mediated natural killer cell activation, and monocyte/macrophage activation. Compared with standard of care, eculizumab specifically abrogated this histomolecular rejection phenotype and associated with a decreased 3-month rejection incidence rate in patients with complement-activating DSAs (56%; 95% confidence interval [95% CI], 38% to 74% versus 19%; 95% CI, 8% to 35%; P=0.001) but not in those with noncomplement-activating DSAs (9%; 95% CI, 2% to 25% versus 13%; 95% CI, 2% to 40%; P=0.65). In conclusion, circulating complement-activating anti-HLA DSAs are associated with a specific histomolecular kidney allograft rejection phenotype that can be abrogated by complement inhibition.

11 January 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
ATAnat R. Tambur
Anat R. Tambur
OBOriol Bestard
Oriol Bestard
PCPatricia Campbell
Patricia Campbell
ACAnita S. Chong
Anita S. Chong
MCMarta Crespo
Marta Crespo
PNPeter Nickerson
Peter Nickerson
The Sensitization in Transplantation: Assessment of Risk workgroup is a collaborative effort of the American Society of Transplantation and the American Society of Histocompatibility and Immunogenetics that aims at providing recommendations for clinical testing, highlights gaps in current knowledge, and proposes areas for further research to enhance histocompatibility testing in support of solid organ transplantation. This report provides updates on topics discussed by the previous Sensitization in Transplantation: Assessment of Risk working groups and introduces 2 areas of exploration: non-human leukocyte antigen antibodies and utilization of human leukocyte antigen antibody testing measurement to evaluate the efficacy of antibody-removal therapies.

21 July 2014 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MLMarc Lúcia
Marc Lúcia
ECElena Crespo
Elena Crespo
EMEdoardo Melilli
Edoardo Melilli
JCJosep M. Cruzado
Josep M. Cruzado
SLSergi Luque
Sergi Luque
OBOriol Bestard
Oriol Bestard
Background. Cytomegalovirus (CMV) infection remains a major complication after kidney transplantation. Baseline CMV risk is typically determined by the serological presence of preformed CMV-specific immunoglobulin (Ig) G antibodies, even though T-cell responses to major viral antigens are crucial when controlling viral replication. Some IgG-seronegative patients who receive an IgG-seropositive allograft do not develop CMV infection despite not receiving prophylaxis. We hypothesized that a more precise evaluation of pretransplant CMV-specific immune-sensitization using the B and T-cell enzyme-linked immunospot assays may identify CMV-sensitized individuals more accurately, regardless of serological evidence of CMV-specific IgG titers. Methods. We compared the presence of preformed CMV-specific memory B and T cells in kidney transplant recipients between 43 CMV IgG–seronegative (sR−) and 86 CMV IgG–seropositive (sR+) patients. Clinical outcome was evaluated in both groups. Results. All sR+ patients showed a wide range of CMV-specific memory T- and B-cell responses. High memory T- and B-cell frequencies were also clearly detected in 30% of sR− patients, and those with high CMV-specific T-cell frequencies had a significantly lower incidence of late CMV infection after prophylactic therapy. Receiver operating characteristic curve analysis for predicting CMV viremia and disease showed a high area under the receiver operating characteristic curve (>0.8), which translated into a high sensitivity and negative predictive value of the test. Conclusions. Assessment of CMV-specific memory T- and B-cell responses before kidney transplantation among sR− recipients may help identify immunized individuals more precisely, being ultimately at lower risk for CMV infection.

7 August 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SLSergi Luque
Sergi Luque
MLMarc Lúcia
Marc Lúcia
EMEdoardo Melilli
Edoardo Melilli
CLCarmen Lefaucheur
Carmen Lefaucheur
MCMarta Crespo
Marta Crespo
OBOriol Bestard
Oriol Bestard
Antibody‐mediated rejection (ABMR) is defined by specific histopathological lesions and evidence of circulating donor‐specific antibodies (DSA). While DSA are not always detectable, monitoring donor‐reactive memory B‐cells (mBC) could recognize at‐risk patients of developing ABMR. Peripheral donor‐reactive mBC using a novel HLA B‐cell ELISpot assay, serum DSA and numbers of different B‐cell subsets were assessed in 175 consecutive kidney transplants undergoing either for‐cause or 6 and 24‐month surveillance biopsies for their association with main histological lesions of ABMR and impact on allograft outcome. In 85 incident for‐cause biopsies, high frequencies of donor‐reactive mBC were detected in all 16(100%) acute ABMR/DSA+ and most chronic ABMR, with or without DSA (24/30[80%] and 21/29[72.4%], respectively). In a longitudinal cohort of 90 non‐sensitized patients, a progressively higher expansion of donor‐reactive mBC than de novo DSA was observed at 6 and 24 months (8.8% vs 7.7% and 15.5% vs 11.1%, respectively) and accurately identified patients with on‐going subclinical ABMR (AUC=0.917 and AUC=0.809, respectively). An unsupervised hierarchical cluster analysis revealed a strong association between donor‐reactive mBC with main fundamental allograft lesions associated to ABMR and conferred a significant deleterious impact on graft outcome.

10 August 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
AFAlexandre Favà
Alexandre Favà
DCDavid Cucchiari
David Cucchiari
NMNuria Montero
Nuria Montero
NTNestor Toapanta
Nestor Toapanta
FCFrancisco J. Centellas
Francisco J. Centellas
EMEdoardo Melilli
Edoardo Melilli
Kidney transplant recipients might be at higher risk for severe coronavirus disease 2019 (COVID‐19). However, risk factors for relevant outcomes remain uncertain in this population. This is a multicentric kidney transplant cohort including 104 hospitalized patients between Mar 4 and Apr 17, 2020. Risk factors for death and acute respiratory distress syndrome (ARDS) were investigated, and clinical and laboratory data was analyzed. The mean age was 60 years. Forty‐seven patients (54.8%) developed ARDS. Obesity was associated to ARDS development (OR 2.63; p=0.04). Significant age differences were not found among patients developing and not developing ARDS (61.3yr vs 57.8yr, p=0.16). Seventy‐six (73%) patients were discharged while 28 (27%) died. Death was more common among the elderly (55yr and 70.8yr, p<0.001) and those with preexisting pulmonary disease (OR 2.89 , p=0.009). At admission, higher baseline lactate dehydrogenase (257 IU/ml vs 358 IU/ml, p=0.001) or ARDS conferred higher risk of death (HR 2.09, p=0.044). In our cohort, ARDS was equally present among young and old kidney recipients. However, the elderly might be at higher risk of death, along with those showing higher baseline LDH at admission.

4 May 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DYDaniel Yoo
Daniel Yoo
VGValentin Goutaudier
Valentin Goutaudier
GDGillian Divard
Gillian Divard
JGJuliette Gueguen
Juliette Gueguen
BABrad C. Astor
Brad C. Astor
ALAlexandre Loupy
Alexandre Loupy